Tumor necrosis factor-a impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans: Diverse vascular actions of a pleiotropic cytokine  by Chia, Stanley et al.
302A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC March 19.2003 
1181-124 Statin Promotes Coronary Collateral Circulation and 
Induces the Regression of Left Ventricular Mass in 
Patients With Angina 
Shin-ichiro Miura. Hiroaki Nishikawa, Masahiro Fujino, Bo Zhang, Hidekl Shimomura. 
Hidekazu Arai, Akira Kawamura, Yashihiro Tsuchiya, Kunihiro Matsuo, Keijiro Saku, 
Fukuoka University, Fukuoka, Japan, Fukuoka Tokusyukai Hospital, Fukuoka, Japan 
Background: There is evidence that hydroxymethylglutaryl coenzyme A reductase inhibi- 
tors (statins) promote collateral circulation (CC) in ischemic limbs and induce the regres- 
sion of left ventricular mass (LVM) in animal models. Therefore, we investigated that the 
treatment with statin may associate with the development of coronary CC (CCC) as 
assessed by Rentrop Score (RS) or the regresston of LVM index (LVMI) as assessed by 
echocardiography in patients with angina. 
Methods: The subjects included 304 patients with angina who underwent coronary 
angiography. Study 1: Subjects who received pravastatin with one (iv), two (2V) or three 
(3V) significantly stenosed vessels were defined as cases (n=42), and age, sex and body 
mass index (BMI)-matched controls without statin treatment (n=lOO) were selected. 
Study 2: Those who received pravastatin or simvastatin were defined as cases (n=66), 
and age, sex and BMI-matched controls (n=l27) ware selected. 
Results: Study 1: The cases included a higher percentage of 3V patients with RS>l than 
the controls but there was no difference among 1V and 2V patients, suggesting that sta- 
tin was associated with CCC independent of the number of stenosed vessels. Patients 
with 3V disease who ware treated with statin were most likely (odds ratio:l7.4(4.4-115)) 
to develop CCC. as assessed by a multiple logistic regression analysis. Study 2: The 
cases showed a significant decrease in LVMI (126g/m2) compared to the controls (146gl 
m2). Although the cases had a significantly higher percentage of patients with hyperten- 
sion (HT) and calcium antagonist (Can) treatment than the controls. there was no rela- 
tionship between LVMI and HT or CaA treatment. Although the cases had significantly 
more stenosed vessels than the controls, there was a significant effect of interaction 
between LVMI with statin treatment and the number of stenosed vessels as assessed by 
ANCOVA. 
Conclusions: Treatment with statin was associated with the existence of CCC and the 
regression of LVMI in patients with angina, suggesting that these effects may play a role 
in the pkiotropic effects of stahn and may be beneficial in coronary heart disease. 
1181-125 Statins in General and Atorvastatin in Particular Do Not 
Affect Platelet Inhibition With Clopidogrel During 
Coronary Stenting 
Victor L. Serebruany, Alex I. Malinin, Steven R. Stelnhubl, Kevin P. Callahan, Paul A. 
Gurbel, Sinai Hospital, Johns Hopkins University, Baltimore. MD 
Background: Platelet activation following srent implantation is well documented and 
may affect both short- and long-term clinical outcomes. Clopidogrel is widely used lo pro- 
duce sustained platelet inhibition in order to prevent further ischemic events in pahents 
with atherothrombosis. Certain clinical scenarios exist when treatment with clopidogrel is 
combined with the chronic use of statins. It has been recently reported that some statins, 
and atorvastatin in particular, may selectively interfere with clopidogrel. limiting the ability 
of this ADP-receptor blocker to inhibit platelet function. 
Methods: We analyzed the data from the PRONTO elavix Reduction of New Ihrombus 
Occurrence) trial, which evaluated platelet inhibition produced by loading dose clopi- 
dogral pre- and post-stenting to determine whether the use of statins influence the ability 
of clopidogrel lo inhibit platelets. Platelets were assessed by conventional plasma aggre- 
gometry induced by 5pM ADP and by expression of GP llbillla (CD41 b). and PECAM-1 
(CD31) by whole blood flow cytometry at baseline, at discharge, and at day 5 following 
stem implantation. 
Results: Data from 100 patients were analyzed. Twenty-five patients were treated with a 
stahn, (9 of those patients received atorvastatin) and 75 were not on statin therapy. 
Platelet inhibition by clopidogrel was Identical in all groups, and resulted in 3540% inhibi- 
tion of aggregation, more than 50% reduction of GP Ilb/llla expression, and 40-45% 
reduction of PECAM-1 expression at day 5 when compared with the baseline values. 
These effects were independent of statin use. 
Conclusion: The study results suggest there are no apparent Interactions between clo- 
pidogrel and statIns. 
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856-l Reduced Endothelial Nitric Oxide Synthase Activity and 
Concentration in Umbilical Veins From Maternal 
Cigarette Smokers 
Malene R. Andersen, Line R. Walker, Steen Stender, Gent&e Hospital, University of 
Copenhagen, Hellerup, Denmark 
Background. The study aimed to investigate the effect of maternal cigarette smoking on 
endothelial nitric oxide synthase (eNOS) activity and concentration in the fetal umbilical 
vein, and to relate rhe findings to the size of the newborn. 
Methods. Fourty-four nonsmoking and 30 smoking (average 15 cigarettes/day) women, 
living in a small area just north of Copenhagen, were Included in the study. Umbilical vein 
endothelial cells were isolated Immediately after delivery. The eNOS activity was deter- 
mined in the samples by the conversion of ‘?-L-arginine to “C-L-citrulline, and the 
eNOS concentration by a human eNOS immunoassay. 
Results. The two aroups of women matched for sociodemoaraohlc and clinical charac- _ _ 
teristics. However, nonsmokers had a higher occupational status than smokers (Regis- 
trar General’s social class 2.1+/-0.1 versus 2.6+/-0.1. kO.001). Newborns of smokers 
had a lower weight (g 3396+/-64 versus 3649+/-58, P=O.O14) and a smaller head circum- 
ference (cm 34.1+/-0.3 versus 35.1+/-0.2, P=O.O02) than those of nonsmokers, but simi- 
lar length and abdominal circumference. The eNOS activity in fetal umbilical veins 
exposed to lntrautenne smoking was 40% lower (pmol L-citrullineiminll@ endothelial 
cells 27.1+/-2.2 versus 45.0+/-5.2. kO.006). and the eNOS concentration 32% lower (ng 
eNOS/lC@ endothelial cells 1.7+/-0.2 versus 2.5+1-0.3, P-0.053) than in nonsmokers. 
The eNOS activity was associated with eNOS concentration (r=O.61, P<O.OOl) and the 
newborn weight (r=O.26, P=O.O14). Multiple regression analysis showed that the reduc- 
tion in eNOS activity associated with smoking was reduced by 40% when adjusting for 
eNOS concentration, and the reduction in birth weight by 26% when adjusting for eNOS 
activity. 
Conclusion. The findings suggest that maternal smoking reduces nitric oxide production 
in the fetal circulation. This may contnbute to retarded growth due to the subsequent 
endothelial dysfunction with reduction of dilatory capacity og the vessels. 
2:15 p.m. 
856-2 Tumor Necrosis Factor-a Infusion Impairs Endothelial 
Function and Induces Endothelial and Metabolic Insulin 
Resistance in Humans 
Helena Dominauez Christian Rask-Madsen, Nikolai Ihlemann, Thomas Hermann, Lars 
Kober, Christian Tarp-Pedersen. Gent&e University Hospital, Hellerup, Denmark, Joslin 
Diabetes Center, Harvard University, Boston, MA 
Background: Tumor necrosis factor-alpha (TNF) levels are elevated In patients with 
acute coronary syndrome and in patients with type 2 diabetes. TNF impairs glucose 
uptake in animal models and in vitro. The aim of this study was lo examine whether TNF 
infusion acutely impairs endothelial function and both insulin-stimulated endothelial func- 
tion and glucose uptake in humans. 
Methods: Lean healthy men were studled in the fasting state. Drugs were infused into 
the brachial artery measuring blood flow by venous occlusion plethysmography. Acety- 
choline was used as endothelium-dependent agonist and nitroprusside as endothelium- 
Independent agonist. Each study was based on ihree infusion series given the same day: 
Infusing first the agonist alone, then co-infusing insulin end the agonist and finally co- 
infusing TNF. insulin and the agonist. For control, TNF and insulin were replaced by their 
vehicle in separate groups of volunteers. Glucose uptake was measured as the product 
between the arterial-venous difference of plasma glucose and forearm blood flow and 
expressed in uM [lo0 ml tissue]-’ min.‘. 
Results: There were performed 40 studies. During TNF infusion, local and systemic 
plasma TNF rose from 1.4 to 134+36 ng L” in the perfused arm and lo 6.5+1.4 ng L-’ h 
systemic blood. The flow during maximal acetylcholine stimulation was 12.7+2.3 ml [lo0 
ml tissue].’ min.‘. Insulin co-infuslon enhanced this flow by 22% (p=O.O007). However 
when TNF was co-infused with insulin forearm decreased this flow by 32% to 8.6e2.3 
(p=O.O02) and TNF alone decreased it by 22% (pcO,OOOl). Insulin also enhanced fore- 
arm blood flow during nitroprusside infuston (p<O.OOl) and TNF blunted it (pcO.001). 
Insulin stimulated forearm glucose uptake by 1 .O*O.l (p=O.O2) but this stimulation was 
completely blocked during TNF infusion since glucose uptake changed by -0.2*0.3 
(p=o.5) 
Conclusion: TNF Infused in humans blunts endothelial function and both insulin-stimu- 
lated endothelium-dependent vasodllatation and glucose uptake. 
2:30 p.m. 
856-3 Tumor Necrosis Factor-a Impairs Endothelium- 
Dependent Vasodilatation and Stimulates Local Tissue 
Plasminogen Activator Release in Humans: Diverse 
Vascular Actions of a Pleiotroplc Cytokine 
Stanley Chia. Motaz Qadan, Richard Newton, Chnstopher A. Ludlam, Keith A. Fox, 
David E. Newby, University of Edinburgh, Edinburgh, United Kingdom, Royal Infirmary of 
Edinburgh, Edinburgh, United Kingdom 
Background: Systemic and vascular inflammation contribute lo the pathogenesis of car- 
diovascular disease, potentially through the actions of pro-inflammatory cytokines. The 
studv aims were to assess the direct effects of local intraarterial tumor necrosis factor-a 
(TN&a), interleukin-6 (IL-6) and endotoxin on blood flow and endogenous tissue plasmi- 
nooen activator (t-PA) release in viva In man. Methods: In a double-blind randomized 
placebo-controlled trial, blood flow, plasma cytokine and flbrinolytic factors concentra- 
tions were determined in both forearms of healthy male subjects using venous occlusion 
plethysmography and blood sampling. Ten subjects received intra-brachial infusions of 
TNF-a (80 or 240 nglmin). IL-6 (30 nglmin), en&toxin (100 pglmin) or saline placebo. 
Eight further subjects received intra-brachial infusion of bradykinin (0.1-I nmollmin), ace- 
tylcholine (5.20 pglmin) and sodium nitroprusstde (2-6 pglmin), two hours after pre-treat- 
ment with TNF-a (60 ngimin) or saline placebo. Results: Plasma TNFa concentrations 
Increased to 539*71 and 1164*41 pg/mL during TNFa 60 ng and 240 ng infusion 
(PcO.001). TNF-a, but not IL-6. endotoxin or placebo, caused a slow onset and marked 
Increase in plasma t-PA antigen and activity concentrations in the infused arm (21.1&X8 
ng/mL and 17.7e4.1 IU/mL, PcO.001) that was sustained for 4 hours. This occurred with- 
out an effect on blood flow but was associated with a rise in plasma IL-6 concentrations 
(PcO.05). Compared to placebo, TNF-a pre-treatment impaired endothelium-dependent 
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vasodilatation (P8.03) and resulted in higher plasma t-PA antigen and activity concen- 
trations during bradykinin Infusion (11.3+0.8 vs 6.6~0.5 ng/mL and 16.5t3.9 vs 6.6k2.0 
IU/mL at peak bradykinin dose: PcO.002) and a doubling of estimated net t-PA release 
(PcO.05). Conclusion: Intra-arterial TNF-a causes an acute local vascular inflammation 
associated with a substantial and sustained increase in local t-PA and IL-6 release. TNF- 
a also impairs endothelium-dependent vasomotion and augments acute endothelial t-PA 
release. These findings indicate that TNF-a has potentially adverse and beneficial effects 
on endothelial and vascular function. 
245 p.m. 
856-4 iNOS Is a Mediator of Increased Arterial lntimal 
Thickening Induced by Passive Cigarette Smoke 
Exposure in Mica 
Takeo Anazawa, Paul C. Dimayuga, Hongyan Li, Previn de Silva, Juliana Yano, Kuang- 
Yuh Chyu, Prediman K. Shah, Bojan Cercek, Cedars-Sinai Medical Center, Los Angeles, 
CA 
Background: Active and paswe smoking was associated with increased intimal/medial 
thickening in the Atherosclerosis Risk In Communities study, but molecular mechanisms 
contributing to this risk are incompletely understood. We evaluated the effect of passive 
smoke on arterial response to injury, and the potential role of iNOS gene in smoking 
induced effects on the arterial wall using iNOS -/- mice. 
Methods: Vascular injury was induced by placing a cuff around the right carotid attery. 
Wild type mice and iNOS -I- mice of the same background were exposed to passive 
smoke (1 agarettelday) or filtered room air. Expression of iNOS and PCNA in the arterial 
wall 3 days after injury was determined by immunostaining. Nitrate and nitrite (NOx) level 
3 days after injury was measured by Griess reaction. lntimal thickening was measured 21 
days after injury. 
Results: iNOS expression in wld type mice exposed to passive smoke increased com- 
pared to mice exposed to room air, and was not detected in iNOS -I- mice. lntimal thick- 
ening in iNOS-i- mice exposed to passive smoke was profoundly reduced compared to 
wld type mice exposed to passive smoke (Table). 
Medial areas were similar in all groups of mice. 
Conclusion: Our results suggest that iNOS expression is a key mediator in the aug- 
mented response to injury in mice exposed to cigarette smoke. iNOS may mediate vaso- 






Wild-type + Wild-type + iNOS -/- mice + iNOS -I- mice + 
Room air Passive smoke Room air Passive smoke 




NOx level 22.3~ 7.3 39.1+ 12.8” 14.3 26.6” 12.5 + 6.6 (n=6) 
(lw (n=6) (n=5) @=6) 
lntimal Area 9.2 -+ 7.5 23.3+ 12.9’” 5.5i4.7” 2.1 + 1.6 (n=5) 
(m&x 16) (n=6) (ll=5) (ll=5) 
#p<O.O5 vs iNOS -I- +Passive smoke, ‘~~0.05 vs Wild-type+Room air, @I ~~0.05 vs 
Wild-type+Passive smoke; ANOVA 
3:oo p.m. 
856-5 Cardiovascular Effects of the Endogenous Nitric Oxide 
Synthase Inhibitor Asymmetric Dimathylarginina 
(ADMA) and Evidence for ADMA Metabolism in Humans 
In Vivo 
Vinod Achan Michael Broadhead. Mohammed Malaki. James Leiper. Raymond -3 
MacAllister. Patrick Valiance, University College London, London, Untted Kingdom 
BACKGROUND: Plasma levels of an endogenous NOS inhibitor, asymmetric dimethy- 
latginine (ADMA), are elevated in chronic renal failure, hypertension, and atherosclero- 
sis. ADMA levels are also significantly raised in patients with chronic heart failure (CHF) 
and in animals with CHF induced by coronary artery ligation or rapid pacing. Despite 
these obsewations the cardiovascular effects of a systemic increase in ADMA have not 
been studied in humans. METHODS: In a randomised, double-blind, placebo-controlled 
study using healthy male volunteers, we compared the effects of intravenous low dose 
ADMA and placebo on heart rate, blood pressure, cardiac output and systemic vascular 
resistance (SVR) at rest and during exercise. We also tested the hypothesis that ADMA 
IS metabolised extensively in humans in viva by a family of dimethylarginine dimethylami- 
nohydrolase (DDAH) enzymes. RESULTS: Low dose ADMA reduced heart rate by a 
maximum of 9.2+1.4% from 58.9k2.0 beats per min (PcO.OOl), and reduced cardiac out- 
put by a maximum of 14&1.2% from 4.4+0.3 Umin (PcO.001). ADMA also increased 
mean blood pressure by a maximum of 6.0*1.2% from E&6&3.4 mm Hg (PcO.CQS), and 
increased SVR by a maximum of 23.7t2.1% from 1639.0*91.6 dynes.s.cm-5 (P<O.OOl). 
Handgrip exercise Increased cardiac output in control subjects by a maximum of 
96.8+23.3%. In contrast, those subjects given ADMA increased their cardiac output by 
35.3+10.6% during exercise, representing a significant reduction in the cardiac response 
to exercise (PcO.05). DDAHs metabolise ADMA to citrulline and dimethylamine (DMA). 
Urinary DMA:Cr ratios significantly increased from 1.26kO.32 to 2.73kO.59 following 
ADMA injection (PcO.01). We estimate from this that humans generate approximately 
300umol of ADMA per day, of which approximately 250umol is metabolised by DDAHs. 
CONCLUSIONS: This study defines the cardiovascular effects of a systemic increase in 
ADMA in humans. These are similar to changes seen in diseases associated with ADMA 
accumulation, suggesting that ADMA could directly contribute to their pathogenesis. 
Finally, our data also indicate that ADMA is metabolised by DDAHs extensively in 
humans in viva. 
3:15 pm. 
856-6 Levels of Nitrotyrosina, an Inflammatory Marker 
Generated by Nitric Oxide Derived Oxidants, Is 
Associated With Risk of Coronary Artery Disease 
Mehdi H. Shishehbor, Ronnier J. Aviles, Marie-L”& Brennan, Xiaoming Fu, Marc S. 
Penn. Dennis L. Sprecher, Noyan Gokce, John F. Keaney, Jr., Joseph A. Vita, Stanley L. 
Hazen, The Cleveland Clinic Foundation, Cleveland, OH, Boston University School of 
Medicine, Boston, MA 
Background: Formation of nitric oxide (.NO)-derived oxidants may selve as a mechanism 
linking inflammation to development of atherosclerosis. Nitrotyrosine. a specific marker 
for protein modification by .NO-derived oxidants. is enriched in human atherosclerotic 
lesions and LDL recovered from human atheroma. Whether systemic levels of nitroty- 
rosine predict coronary artery disease (CAD) is not known. 
Methods: Serum nitrotyrosine levels in 262 consecutive patients at a major metropolitan 
medical center were determined by mass spectrometry and correlated with the preva- 
lence of CAD. 
Results: The median nitrotyrosine content of plasma proteins was significantly higher in 
the CAD group (9.13 umoVmol vs. 5.66 umol/mol, P c 0.001). Subjects in the upper quar- 
tile of nitrotyrosine levels had higher risk of CAD (unadjusted odds ratio, 4.06; 95% confi- 
dence interval, 1.94 to 8.50; P < 0.001). After adjusting for Framingham risk factors and 
high sensitive C-reactive protein, upper quartiles of nitrotyrosine remained predictive for 
CAD risk (odds ratio, 3.01; 95% confidence interval, 1.26 to 7.07; P < 0.001). 
Conclusion: Elevated levels of nitrotyrosine, a specific protein modification produced by 
.NO-derived oxidants and which is linked to CAD pathogenesis, serves as a significant 
and independent predictor of CAD risk. These results support a potential role for .NO- 
derived oxidants as an inflammatory mediator in CAD and may have important implica- 
tions for atherosclerosis diagnosis and risk assessment, 
“T 1st 2nd-~ 3rd 4th 
Quartiles of Nitrotyrosine 
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857-l Incidence and Characteristics of Ruptured Plaque in 
Femoro-Poplitaal Arteries 
Yoichiro Honaq Ali Hassan, Krishnankutty Sudhir. Daniel Adelman, Yasuhiro Honda, 
Paul G. Yock, Peter J. Fitzgerald, Stanford University, Stanford, CA, Pharmacyclics Inc., 
Sunnyvale, CA 
Background: Numerous studies have reported the characteristics of atherosclerotic 
lesions with plaque rupture in coronary arteries. However the incidence and characteris- 
tics of plaque rupture in the peripheral circulation have not been well studied. 
Methods: Ninety-seven lesions in 40 patients scheduled for elective angloplasty in either 
the femoral or popliteal arteries were enrolled. IVUS was performed before intervention. 
Lesion inclusion criteria were: (1) segmental, (2) proximal reference % plaque area < 
50%, (3) degree of calcified arc < 90”. Discontinuity of luminal sulfate with a cavity within 
the plaque mass was defined as plaque rupture. Lumen area, vessel area, degree of cal- 
cified arc. plaque eccentricity index (El) and remodeling index (RI: lesion I proximal refer- 
ence vessel area) were measured. 
Results: Plaque rupture was observed in 42 lesions (43%). When lesions with and with- 
out plaque rupture were compared, lumen area, degree of calcified arc and El were iden- 
tical (6.9k3.7 vs.6.9+5.2m& 22+25 vs.25+31’, 0.74*0.16 vs.O.73*0.16, NS). However, 
vessel area and RI were significantly higher in lesion with plaque rupture (30.1*6.0 
vs.26.0*6.9mm? p=O.OOl. 1.09+0.19 vs.O.98+0.16, p=O.OOS). The distribution of remod- 
